Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Evaluation of nanoparticles as oral vehicles for immunotherapy against experimental peanut allergy

Brotons-Canto, Ana, Gamazo, Carlos, Martín-Arbella, Nekane, Abdulkarim, Muthanna, Matías, Jose, Gumbleton, Mark ORCID: https://orcid.org/0000-0002-7386-311X and Irache, Juan M. 2018. Evaluation of nanoparticles as oral vehicles for immunotherapy against experimental peanut allergy. International Journal of Biological Macromolecules 110 , pp. 328-335. 10.1016/j.ijbiomac.2017.09.109

[thumbnail of Evaluation of nanoparticles as oral vehicles for immunotherapy against experimental peanut allergy .pdf]
Preview
PDF - Accepted Post-Print Version
Download (688kB) | Preview

Abstract

The aim of this work was to evaluate the potential application of an original oral immunotherapy, based on the use of nanoparticles, against an experimentally induced peanut allergy. In this context, a roasted peanut extract, containing the main allergenic proteins, were encapsulated into poly(anhydride) nanoparticles. The resulting peanut-loaded nanoparticles (PE-NP) displayed a mean size of about 150 nm and a significantly lower surface hydrophobicity than empty nanoparticles (NP). This low hydrophobicity correlated well with a higher in vitro diffusion in pig intestinal mucus than NP and an important in vivo capability to reach the intestinal epithelium and Peyer’s patches. The immunotherapeutic capability of PE-NP was evaluated in a model of pre-sensitized CDI mice to peanut. After completing therapy of three doses of peanut extract, either free or encapsulated into nanoparticles, mice underwent an intraperitoneal challenge. Anaphylaxis was evaluated by means of assessment of symptom scores and mouse mast cell protease-1 levels (mMCPT-1). PE-NP treatment was associated with significant lower levels of mMCPT-1, and a significant survival rate after challenge, confirming the protective effect of this formulation against the challenge. In summary, this nanoparticle-based formulation might be a valuable strategy for peanut-specific immunotherapy.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Pharmacy
Publisher: Elsevier
ISSN: 0141-8130
Date of First Compliant Deposit: 12 October 2017
Date of Acceptance: 27 September 2017
Last Modified: 07 Nov 2023 00:50
URI: https://orca.cardiff.ac.uk/id/eprint/105475

Citation Data

Cited 22 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics